Millipore Sigma Vibrant Logo
 
プレスリリース
前のページへ戻る
 


News Release
April 17, 2018
Your Contact:
Karen Tiano +49 6151 72 44461

Merck Introduces New Single-use Technologies to Advance Flexible Manufacturing
  • Innovations include first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies
  • Tangential flow filtration capsule, final fill capsule filter and large-scale mixers designed with operators in mind
  • New products reduce risk, improve speed and ease of use

Darmstadt, Germany, April 17, 2018 — Merck, a leading science and technology company, today introduced three new products to support flexible manufacturing of biologics. The innovations, all designed to make single-use bioprocessing easier, safer and more efficient, will be unveiled at the International Pharmaceutical Expo (INTERPHEX), New York City, USA.

They are:

“The biopharmaceutical industry needs flexible manufacturing solutions that reduce long drug development timelines and accommodate shifts in demand, while protecting employees and the environment,” said Andrew Bulpin, head of Process Solutions business, Life Science, at Merck. “Merck’s new bioprocessing innovations demonstrate our commitment to developing superior single-use technologies that will drive implementation of flexible manufacturing technologies around the world.”

At INTERPHEX – the premier pharmaceutical, biotechnology and medical device development and manufacturing event in the U.S. -- Merck introduced its Pellicon® Capsule with Ultracel® Membrane is the first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies. The capsule combines fast, user-friendly and efficient processing of biologics with reliable performance and linear scalability. The capsule also reduces risk of product cross-contamination as well as exposure to highly toxic compounds during processing and disassembly. It is the newest addition to Merck’s industry-leading Pellicon® ultrafiltration product family.

Also introduced at INTERPHEX is Merck’s Millipak® Final Fill Filter. This filter was designed with an angled, innovative aseptic Multi-Purpose Port for sampling, venting and integrity testing through the same port while protecting against microbial contamination and ensuring sterility of the drug product. The stacked disc design maximizes product yield and the transparent housing clearly shows fluid flow during the critical final filtration step.

Merck’s new Mobius® Power MIX 2,500-Litre and 3,000-Litre single-use mixers handle difficult-to-mix buffers, cell culture media powders and other pharmaceutical ingredients. Both large-scale systems incorporate NovAseptic® technology, traditionally used in stainless steel mixers, saving time and enabling more efficient single-use mixing. The new mixers extend Merck’s product line, which now includes single-use mixing at scales ranging from 100 litres to 3,000 litres. All Mobius® Power MIX systems offer easy bag installation and product sampling to save customers’ time.

Merck representatives will be available to discuss these innovative technologies at Booth 2841 at INTERPHEX, April 17–19, at the Javits Center in New York City, USA.

メルクについて
Merck(メルク)はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。